14. Intangible assets other than goodwill
(thousands of €) |
Software & |
Licences, rights, technology and |
Exclusive rights |
Contract costs |
Total |
|---|---|---|---|---|---|
Acquisition value |
|
|
|
|
|
|
|
|
|
|
|
On 1 January 2022 |
24,554 |
39,929 |
- |
15,384 |
79,868 |
Impact of acquisitions of businesses |
2,610 |
32,240 |
89,720 |
|
124,570 |
Additions |
1,126 |
8,423 |
|
|
9,549 |
Sales and disposals |
(913) |
(36,298) |
|
|
(37,211) |
Translation differences |
|
(36) |
|
|
(36) |
On 31 December 2022 |
27,377 |
44,258 |
89,720 |
15,384 |
176,740 |
Additions |
567 |
|
|
|
567 |
Sales and disposals |
(930) |
(948) |
|
|
(1,878) |
Translation differences |
|
(139) |
|
|
(139) |
On 31 December 2023 |
27,014 |
43,171 |
89,720 |
15,384 |
175,290 |
|
|
|
|
|
|
Amortization and impairment |
|
|
|
|
|
|
|
|
|
|
|
On 1 January 2022 |
11,977 |
4,199 |
- |
3,588 |
19,765 |
Amortization |
4,146 |
333 |
6,154 |
1,538 |
12,171 |
Impairment |
|
35,666 |
|
|
35,666 |
Sales and disposals |
(913) |
(36,298) |
|
|
(37,211) |
Translation differences |
|
(4) |
|
|
(4) |
On 31 December 2022 |
15,210 |
3,896 |
6,154 |
5,126 |
30,387 |
Amortization |
4,291 |
1,426 |
11,637 |
1,538 |
18,892 |
Sales and disposals |
(927) |
(948) |
|
|
(1,875) |
Translation differences |
|
(20) |
|
|
(20) |
On 31 December 2023 |
18,574 |
4,354 |
17,791 |
6,664 |
47,384 |
|
|
|
|
|
|
Carrying amount |
|
|
|
|
|
|
|
|
|
|
|
On 31 December 2022 |
12,167 |
40,362 |
83,566 |
10,258 |
146,354 |
On 31 December 2023 |
8,440 |
38,817 |
71,929 |
8,720 |
127,906 |
Impact of acquisition of businesses in 2022 refers to the acquisition of CellPoint and AboundBio. We refer to note 27 “Business combinations during the prior period”.
The exclusive rights refer to our exclusivity contract with Lonza and are depreciated until the beginning of March 2030, in accordance with the contract.
In 2022 we recorded an impairment of €26.7 million on previously capitalized upfront fees related to our collaboration with Molecure on the dual chitinase inhibitor OATD-01 (GLPG4716) in fibrosis, and impairments of €8.9 million on intangible assets related to other discontinued projects.
On 31 December 2023, our balance sheet did not hold any internally generated assets capitalized as intangible asset.